Kenneth Anderson

Kenneth Anderson is a pioneer in the development of proteasome inhibitors for multiple myeloma, with bortezomib being one of the most successful cancer drugs to emerge from targeting ER stress and proteostasis. His clinical and translational research established that inhibiting the proteasome overwhelms plasma cells with misfolded proteins, inducing lethal ER stress through UPR hyperactivation. He led pivotal trials that established bortezomib as the backbone of myeloma therapy and characterized ER stress induction as its mechanism of action. His work created the template for proteostasis-targeting cancer therapy.